

DAFTAR PUSTAKA

1. Morgan, G. E., Mikhail, M. S., Murray, M. J. & Larson, C. P. *Clinical anesthesiology*. vol. 361 (Lange Medical Books/McGraw-Hill New York, 2006).
2. Smitha, K. S. *et al.* Comparison of two different doses of dexmedetomidine in attenuating hemodynamic changes during laryngoscopy. *J. Evol. Med. Dent. Sci.* 3, 13501–13509 (2014).
3. VoLJ Ta, A. *et al.* Effect of diabetes mellitus on the cardiovascular responses to induction of anaesthesia and tracheal intubation. *Br. J. Anaesth.* 71, 258–261 (1993).
4. Kovac, A. L. Controlling the hemodynamic response to laryngoscopy and endotracheal intubation. *J. Clin. Anesth.* 8, 63–79 (1996).
5. Yoo, K. Y., Lee, J., Kim, H. S. & Im, W. M. Hemodynamic and catecholamine responses to laryngoscopy and tracheal intubation in patients with complete spinal cord injuries. *J. Am. Soc. Anesthesiol.* 95, 647–651 (2001).
6. Derbyshire, D. R. *et al.* Plasma catecholamine responses to tracheal intubation. *BJA Br. J. Anaesth.* 55, 855–860 (1983).
7. Wong, S. S. C. & Irwin, M. G. Peri-operative cardiac protection for non-cardiac surgery. *Anaesthesia* 71, 29–39 (2016).
8. Banerjee, A. & MisLJ Ta, S. Use of preoperative single dose ivabradine for perioperative hemodynamic stabilization during non-cardiac elective surgery under general anaesthesia: a pilot study. *J. Clin. Med. Res.* 13, 343 (2021).
9. De Santis, V., Frati, G., Greco, E. & Tritapepe, L. Ivabradine: a preliminary observation for a new therapeutic role in patients with multiple organ dysfunction syndrome. *Clin. Res. Cardiol.* 103, 831–834 (2014).
10. Prince, M. Beta blockers in the perioperative period. *Br. J. Hosp. Med.* 81, 1–2 (2020).
11. Packiasabapathy, S. & Subramaniam, B. Optimal perioperative blood pressure management. *Adv. Anesth.* 36, 67–79 (2018).
12. Ibrahim, A. N. & Atallah, R. Y. Ivabradine versus propranolol given orally

- in microlaryngoscopic surgeries in attenuating stress response: A comparative prospective double blind randomized study. *Egypt. J. Anaesth.* 32, 503–511 (2016).
13. Vincent, J.-L. *et al.* Perioperative cardiovascular monitoring of high-risk patients: a consensus of 12. *Crit. Care* 19, 1–12 (2015).
 14. Sapio, P. Lo *et al.* The role of ivabradine in the incidence of perioperative coronary complications in patients undergoing vascular surgery. *Int. J. Cardiol.* 168, 4352–4353 (2013).
 15. Arora, V., Awasthi, G., Singh, R. B. & Singh, V. Study of attenuation of hemodynamic response to laryngoscopy and endotracheal intubation using intra-oral ivabradine. *Anesth. essays Res.* 13, 138 (2019).
 16. Nair, S. *et al.* The effect of β -blocker premedication on the surgical field during endoscopic sinus surgery. *Laryngoscope* 114, 1042–1046 (2004).
 17. Amr, Y. M. & Amin, S. M. Effects of preoperative β -blocker on blood loss and blood transfusion during spinal surgeries with sodium nitroprusside–controlled hypotension. *Saudi J. Anaesth.* 6, 263 (2012).
 18. Nguyen, L. S. *et al.* Intravenous ivabradine versus placebo in patients with low cardiac output syndrome treated by dobutamine after elective coronary artery bypass surgery: a phase 2 exploratory randomized controlled trial. *Crit. care* 22, 1–9 (2018).
 19. Pinto, B. B. & Walder, B. Heart rate as a predictor and a therapeutic target of cardiac ischemic complications after non-cardiac surgery. A narrative review. *Trends Anaesth. Crit. Care* 22, 26–32 (2018).
 20. Kunwer, R., Joshi, M. & Pathak, S. Prevention of Haemodynamic Changes during Laryngoscopy and Endotracheal Intubation-A Clinical Study of Oral Ivabradine. *Int. J. Contemp. Med. Res. ISSN* 3, 2393–915 (2016).
 21. Nørskov, A. K., Rosenstock, C. V., Wetterslev, J. & Lundstrøm, L. H. Incidence of unanticipated difficult airway using an objective airway score versus a standard clinical airway assessment: the DIFFICAIR trial–trial protocol for a cluster randomized clinical trial. *Trials* 14, 1–12 (2013).
 22. JAaPA, K. Airway assessment and prediction of the difficult airway. *Carin*

- A. Hagb. MD FCAAMaMFAM. Hagb. BENUMOF'S Airw. Manag. 4TH Ed. Philadelphia Elsevier Inc 185–196 (2018).*
23. Levine, W. C. *et al. Clinical Anesthesia Procedures of the Massachusetts General Hospital: Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School.* (Lippincott Williams & Wilkins, 2012).
 24. Avva, U., Lata, J. M. & Kiel, J. Airway Management. *StatPearls [Internet]* (2021).
 25. Pani, N. & Rath, S. K. Regional & topical anaesthesia of upper airways. *Indian J. Anaesth.* 53, 641 (2009).
 26. Joffe, A. M. & Deem, S. A. Physiologic and pathophysiologic responses to intubation. in *Benumof and Hagberg's Airway Management* 184–198 (Elsevier, 2013).
 27. Brown, D. L. *Atlas of regional anesthesia.* (Elsevier Health Sciences, 2010).
 28. Heusch, G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. *Br. J. Pharmacol.* 153, 1589–1601 (2008).
 29. Campbell, R. L. & Langston, W. G. A comparison of cardiac rate-pressure product and pressure-rate quotient in healthy and medically compromised patients. *Oral Surgery, Oral Med. Oral Pathol. Oral Radiol. Endodontology* 80, 145–152 (1995).
 30. Gunawan, S. G., Setiabudy, R. & Nafrialdi, E. *Farmakologi dan Terapi edisi 5. Jakarta Dep. Farmakol. dan Ter. FKUI (2007).*
 31. Khan, M. I. G. & Messerli, F. H. *Cardiac drug therapy.* (Springer, 2007).
 32. Rosa, G. M., Ferrero, S., Ghione, P., Valbusa, A. & Brunelli, C. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. *Expert Opin. Drug Metab. Toxicol.* 10, 279–291 (2014).
 33. Tse, S. & Mazzola, N. Ivabradine (Corlanor) for heart failure: the first selective and specific IF inhibitor. *Pharm. Ther.* 40, 810 (2015).
 34. Raghuram, C. G., Singh, D. & Kabra, A. V. Attenuation of haemodynamic

- response to laryngoscopy and endotracheal intubation using intra oral ivabradine: a clinical study. *J. Evol. Med. Dent. Sci.* 3, 9944–9956 (2014).
35. Sulfi, S. & Timmis, A. D. Ivabradine—the first selective sinus node If channel inhibitor in the treatment of stable angina. *Int. J. Clin. Pract.* 60, 222–228 (2006).
 36. Koruth, J. S., Lala, A., Pinney, S., Reddy, V. Y. & Dukkipati, S. R. The clinical use of ivabradine. *J. Am. Coll. Cardiol.* 70, 1777–1784 (2017).
 37. Psotka, M. A. & Teerlink, J. R. Ivabradine: role in the cLJ Tonic heart failure armamentarium. *Circulation* 133, 2066–2075 (2016).
 38. Urbanek, I., Kaczmarek, K., Cygankiewicz, I. & Ptaszynski, P. Risk-benefit assessment of ivabradine in the treatment of cLJ Tonic heart failure. *Drug. Healthc. Patient Saf.* 6, 47 (2014).
 39. Swedberg, K. *et al.* Ivabradine and outcomes in cLJ Tonic heart failure (SHIFT): a randomised placebo-controlled study. *Lancet* 376, 875–885 (2010).
 40. Lonjaret, L., Lairez, O., Minville, V. & Geeraerts, T. Optimal perioperative management of arterial blood pressure. *Integr. Blood Press. Control* 7, 49 (2014).
 41. Sastroasmoro, S. & Ismael, S. Dasar-dasar metodologi penelitian klinis Edisi ke-4. *Jakarta Sagung Seto* 376, (2011).